Objective: To report and evaluate intravitreal ganciclovir injections in non-AIDS patients with human cytomegalovirus (HCMV) retinitis.
Design: Retrospective chart review.
Participants: Two SLE patients and one patient post chemotherapy for a non Hodgkin's lymphoma presented with myelosuppression and persistent cytomegalovirus retinitis despite systemic ganciclovir therapy.
Methods: Patients were treated with 100 microL of intravitreal ganciclovir (4 mg/dL), initially given weekly. Systemic anti-CMV medication was stopped, and following quiescence, intravitreal injections were tapered and ultimately stopped based on therapeutic response. Patients were followed periodically for signs of recurrence.
Results: Intravitreal ganciclovir was well tolerated and led to remission of the retinitis in 2 patients. One patient had persistent smouldering disease and reached quiescence using an intravitreal ganciclovir implant. Fluorescence-activated cell sorting analysis in one patient showed the presence of low CD4 and CD8 while treated with systemic ganciclovir, which improved with intravitreal treatment. In another, the low ratio was maintained against cytomegalovirus-specific antigens.
Conclusions: Intravitreal ganciclovir injections should be considered as a treatment option in selected iatrogenically immunocompromised patients with HCMV retinitis. Responses may vary and will require an adjusted approach to treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3129/i09-262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Unusual Case of Exudative Retinal Detachment in a 6-Year-Old Child with Acute Retinal Necrosis.
Ocul Immunol Inflamm
December 2024
Uvea Services, Sankara Nethralaya, Chennai, India.
Purpose: To report a case of exudative retinal detachment (ERD) in a child with Acute retinal necrosis (ARN).
Method: Retrospective Chart Review.
Result: A six-year-old boy presented with anterior uveitis with hypopyon and exudative retinal detachment with peripheral confluent patches of retinitis in the left eye.
Tocilizumab for Cystoid Macular Edema Secondary to Immune Recovery Uveitis in a Patient with Contraindications to Long-Term Systemic Corticosteroid.
Yale J Biol Med
December 2024
Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
: To report a case of cystoid macular edema (CME) secondary to immune recovery uveitis (IRU) in a patient with previous history of cytomegalovirus (CMV) retinitis and leukemia, which was successfully treated with tocilizumab (TCZ), an interleukin-6 (IL-6) receptor antagonist. : The clinical records of the case were reviewed, focusing on demographics, image findings, and clinical course. : A 17-year-old female with a past medical history of T-cell acute lymphoblastic leukemia (T-ALL) undergoing chemotherapy for two years presented with active CMV retinitis.
View Article and Find Full Text PDFAntiviral therapy for cytomegalovirus retinitis: A systematic review and meta-analysis.
Surv Ophthalmol
January 2025
Programme for Ocular Inflammation & Infection Translational Research, National Healthcare Group, Singapore, Singapore; Department of Bioinformatics, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, UK; UCL-Institute of Ophthalmology, UK; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; Duke NUS Medical School, Singapore; Singapore Eye Research Institute, Singapore.
Article Synopsis
- Cytomegalovirus retinitis (CMVR) is a major cause of blindness in advanced AIDS patients, with varied treatment approaches due to the lack of established guidelines.
- A review of 59 studies revealed an 18% improvement in visual acuity and a 90% rate of inflammation resolution, with ganciclovir being the most commonly used antiviral treatment.
- Notably, patients on antiretroviral therapy (ART) had a significantly lower recurrence rate of inflammation compared to those not on ART, and the most common side effect reported was neutropenia related to ganciclovir.
Acute Retinal Necrosis Associated with Epstein-Barr Virus Successfully Treated with Antiviral Treatment: A Case Report.
Microorganisms
October 2024
Department of Ophthalmology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea.
Article Synopsis
- Epstein-Barr virus (EBV) is a rare but serious cause of acute retinal necrosis (ARN), typically resulting in poor outcomes and limited antiviral treatment options.
- An 85-year-old man diagnosed with EBV ARN experienced significant visual disturbances and was treated with a combination of intravenous acyclovir and intravitreal ganciclovir.
- After seven weeks of treatment, the patient's vision improved from 20/200 to 20/100, and the size of the necrotic lesion reduced, suggesting that this combination therapy can be effective for EBV-related ARN.
Subacute Toxic Pigmentary Retinopathy after Intravitreal Ganciclovir Injection: A Case Report.
Korean J Ophthalmol
December 2024
Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!